Literature DB >> 32193830

Polymyxin for the treatment of intracranial infections of extensively drug-resistant bacteria in children after neurosurgical operation.

Jing Ye1, Lin-Hua Tan1, Zhi-Peng Shen2, Yun-Song Yu3, Deng-Ming Lai4, Jie Fan5,6,7, Qiang Shu8.   

Abstract

BACKGROUND: Increased meningitis caused by extensively drug-resistant bacillary presents a significant challenge in antibiotic selection. The aim of our study was to evaluate the efficacy and safety of polymyxin in the treatment of post-neurosurgical meningitis due to the extensively drug-resistant bacillary in children.
METHODS: We performed a retrospective study on post-neurosurgical meningitis caused by the extensively drug-resistant bacillary in children, who were treated with polymyxin for ≥ 3 days.
RESULTS: Among five post-neurosurgical meningitis cases that were included, the children were infected by Acinetobacter baumannii (n = 3), Klebsiella pneumonia (n = 1), and Pseudomonas aeruginosa (n = 1). The drug susceptibility test showed that they were extensively drug-resistant bacillary. Two patients received intravenous polymyxin E. Three children received intravenous combined with intraventricular injection of polymyxin B. One patient infected by Klebsiella pneumonia eventually died of septic shock. No serious adverse effects of polymyxin were observed.
CONCLUSIONS: Polymyxin is a safe and effective therapy for post-neurosurgical, multidrug-resistant bacillary meningitis in children.

Entities:  

Keywords:  Drug resistance; Meningitis; Neurosurgical procedures; Polymyxin

Year:  2020        PMID: 32193830     DOI: 10.1007/s12519-020-00350-8

Source DB:  PubMed          Journal:  World J Pediatr            Impact factor:   2.764


  3 in total

1.  Targeted surveillance and infection-related risk factors of nosocomial infection in patients after neurosurgical operation.

Authors:  Lixi Jiang; Linping Guo; Rentao Li; Suzhen Wang
Journal:  Pak J Pharm Sci       Date:  2017-05       Impact factor: 0.684

2.  Risk factors for nephrotoxicity onset associated with polymyxin B therapy.

Authors:  Yanina Dubrovskaya; Nishant Prasad; Yuman Lee; Diana Esaian; Deborah A Figueroa; Vincent H Tam
Journal:  J Antimicrob Chemother       Date:  2015-02-03       Impact factor: 5.790

3.  Pseudomonas aeruginosa causing nosocomial meningitis in neonates and children: overview of 15 cases within 10 years.

Authors:  A Ondrusova; E Kalavsky; B Rudinsky; F P Freybergh; F Bauer; Jozef Miklosko; M Huttova; P Kisac; R Cauda
Journal:  Neuro Endocrinol Lett       Date:  2007-06       Impact factor: 0.765

  3 in total
  3 in total

1.  CD19 CAR T Cells for the Treatment of Pediatric Pre-B Cell Acute Lymphoblastic Leukemia.

Authors:  Holly L Pacenta; Theodore W Laetsch; Samuel John
Journal:  Paediatr Drugs       Date:  2020-02       Impact factor: 3.022

2.  Intrathecal Injection of Tigecycline and Polymyxin B in the Treatment of Extensively Drug-Resistant Intracranial Acinetobacter baumannii Infection: A Case Report and Review of the Literature.

Authors:  Ziyu Li; Yuling An; Lijuan Li; Huimin Yi
Journal:  Infect Drug Resist       Date:  2022-03-31       Impact factor: 4.003

Review 3.  Differential Diagnosis and Hospital Emergency Management for Fastlane Treatment of Central Nervous System Infection Under the COVID-19 Epidemic in Changsha, China.

Authors:  Haojun Yang; Yunfang Chi; Zhuohui Chen; Yishu Fan; Haiyue Wu; Xinhang Hu; Tong Wu; Bo Xiao; Mengqi Zhang
Journal:  Front Neurol       Date:  2020-10-20       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.